Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Modulation of the Extent of Ischemic Brain Damage by Protecting the Endothelial Glycocalyx With Low-Dose Albumin Administration

NCT07415655 is registered in ClinicalTrials.gov with University Hospital Hradec Kralove as lead sponsor.

NCT NCT07415655
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07415655 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Modulation of the Extent of Ischemic Brain Damage by Protecting the Endothelial Glycocalyx With Low-Dose Albumin Administration
Lead sponsor
University Hospital Hradec Kralove
Phase
Phase 2
Overall status
Recruiting
Start date
February 3, 2026
Completion date
February 1, 2028
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ischemic stroke